ARTICLE | Product Development
Making of Mepsevii
Why Ultragenyx developed Mepsevii for ultra-rare indication MPS VII
December 8, 2017 6:13 PM UTC
It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio of products for larger Orphan indications.
FDA approved Mepsevii on Nov. 15 to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome), an indication with only 200 patients worldwide...
BCIQ Company Profiles